ESPR Esperion Therapeutics Inc

Price (delayed)

$24.68

Market cap

$695.78M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.89

Enterprise value

$935.35M

Highlights
ESPR's revenue is up by 2.7% since the previous quarter
The net income has grown by 41% YoY but it has contracted by 9% from the previous quarter
Esperion Therapeutics's EPS has increased by 39% YoY but it has decreased by 13% QoQ
The equity has shrunk by 180% QoQ
Esperion Therapeutics's debt has surged by 173% YoY and by 26% QoQ

Key stats

What are the main financial stats of ESPR
Market
Shares outstanding
28.19M
Market cap
$695.78M
Enterprise value
$935.35M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
2.75
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4
Earnings
Revenue
$233.69M
EBIT
-$129.61M
EBITDA
-$129.02M
Free cash flow
-$105.58M
Per share
EPS
-$5.89
Free cash flow per share
-$4.06
Book value per share
-$9.64
Revenue per share
$8.99
TBVPS
$10.72
Balance sheet
Total assets
$278.61M
Total liabilities
$548M
Debt
$457.51M
Equity
-$269.39M
Working capital
$174.68M
Liquidity
Debt to equity
-1.7
Current ratio
2.78
Quick ratio
2.23
Net debt/EBITDA
-1.86
Margins
EBITDA margin
-55.2%
Gross margin
98.2%
Net margin
-66.9%
Operating margin
-55.5%
Efficiency
Return on assets
-51.5%
Return on equity
N/A
Return on invested capital
-52.2%
Return on capital employed
-71.7%
Return on sales
-55.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ESPR stock price

How has the Esperion Therapeutics stock price performed over time
Intraday
-0.48%
1 week
2.32%
1 month
7.87%
1 year
-44.74%
YTD
-5.08%
QTD
-12.01%

Financial performance

How have Esperion Therapeutics's revenue and profit performed over time
Revenue
$233.69M
Gross profit
$229.54M
Operating income
-$129.77M
Net income
-$156.24M
Gross margin
98.2%
Net margin
-66.9%
ESPR's operating margin has surged by 99% year-on-year but it is down by 4.1% since the previous quarter
Esperion Therapeutics's net margin has surged by 99% YoY but it has decreased by 6% QoQ
The company's operating income rose by 49% YoY but it fell by 7% QoQ
The net income has grown by 41% YoY but it has contracted by 9% from the previous quarter

Growth

What is Esperion Therapeutics's growth rate over time

Valuation

What is Esperion Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
2.75
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4
Esperion Therapeutics's EPS has increased by 39% YoY but it has decreased by 13% QoQ
The equity has shrunk by 180% QoQ
The price to sales (P/S) is 37% lower than the last 4 quarters average of 4.4
ESPR's revenue is up by 2.7% since the previous quarter

Efficiency

How efficient is Esperion Therapeutics business performance
Esperion Therapeutics's return on sales has surged by 99% YoY but it has decreased by 4.5% QoQ
The return on invested capital has surged by 76% year-on-year and by 25% since the previous quarter
The return on assets has surged by 53% year-on-year

Dividends

What is ESPR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ESPR.

Financial health

How did Esperion Therapeutics financials performed over time
The total assets is 49% less than the total liabilities
ESPR's total liabilities has surged by 138% year-on-year and by 22% since the previous quarter
The total assets has soared by 55% YoY but it has contracted by 21% from the previous quarter
The equity has shrunk by 180% QoQ
Esperion Therapeutics's debt has surged by 173% YoY and by 26% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.